Antibody escape by polyomavirus capsid mutation facilitates neurovirulence.
Matthew D LauverDaniel J GoetschiusColleen S Netherby-WinslowKatelyn N AyersGe JinDaniel G HaasElizabeth L FrostSung Hyun ChoCarol M BatorStephanie M BywatersNeil D ChristensenSusan L HafensteinAron E LukacherPublished in: eLife (2020)
JCPyV polyomavirus, a member of the human virome, causes progressive multifocal leukoencephalopathy (PML), an oft-fatal demyelinating brain disease in individuals receiving immunomodulatory therapies. Mutations in the major viral capsid protein, VP1, are common in JCPyV from PML patients (JCPyV-PML) but whether they confer neurovirulence or escape from virus-neutralizing antibody (nAb) in vivo is unknown. A mouse polyomavirus (MuPyV) with a sequence-equivalent JCPyV-PML VP1 mutation replicated poorly in the kidney, a major reservoir for JCPyV persistence, but retained the CNS infectivity, cell tropism, and neuropathology of the parental virus. This mutation rendered MuPyV resistant to a monoclonal Ab (mAb), whose specificity overlapped the endogenous anti-VP1 response. Using cryo-EM and a custom sub-particle refinement approach, we resolved an MuPyV:Fab complex map to 3.2 Å resolution. The structure revealed the mechanism of mAb evasion. Our findings demonstrate convergence between nAb evasion and CNS neurovirulence in vivo by a frequent JCPyV-PML VP1 mutation.
Keyphrases
- disease virus
- single cell
- endothelial cells
- blood brain barrier
- ejection fraction
- multiple sclerosis
- prognostic factors
- advanced non small cell lung cancer
- stem cells
- resting state
- amino acid
- small molecule
- multiple myeloma
- zika virus
- functional connectivity
- single molecule
- binding protein
- epidermal growth factor receptor
- protein protein
- subarachnoid hemorrhage
- water quality